PBM Pharmacy Networks and Steering: The Promise Behind the Referral

PBM pharmacy network steering fraud concerns false promises or reports about where patients can fill prescriptions, what pharmacies receive and what government programs pay. A pharmacy benefit manager can direct prescriptions through preferred cost sharing, mail-order terms and specialty restrictions, then earn dispensing revenue through its own pharmacy. The business setting the route can also own the destination. If you work in network contracting, pharmacy operations or benefit administration, you may know the rule the patient was given, the exception an affiliate received, or the payment the client never saw.

What a Pharmacy Network Promise Covers

A patient hears where to fill a prescription. Behind that instruction sit separate agreements governing pharmacy participation, reimbursement and access to the manufacturer’s drug. Preferred status affects what the patient pays within the network.

Standard Participation and Preferred Cost Sharing

Medicare Part D’s any willing pharmacy requirement generally gives pharmacies willing to accept the sponsor’s standard terms an opportunity to participate. Those terms must be reasonable and relevant. The Centers for Medicare & Medicaid Services’ pharmacy-access guidance says similarly situated pharmacies must receive the same standard terms, while allowing differences for geography and pharmacy type.

Preferred pharmacies offer lower designated cost sharing within the network. A pharmacy can therefore accept the plan and still cost the patient more to use.

Part D measures retail access from beneficiaries’ locations, with different standards for urban, suburban and rural areas. Mail-order pharmacies do not count toward those retail-access standards. A national directory can look impressive. Which pharmacy can this member actually use?

Mail Order and Extended Supplies

Part D plans offering an extended supply through mail order must make that benefit reasonably accessible through network retail pharmacies too. An extended-supply addendum sets the retail terms. Retail cost sharing can reflect a higher contracted rate. An instruction to use mail order belongs beside the retail addendum and claim response: what did the pharmacy agree to dispense, and what was the patient asked to pay?

Specialty Access and the Product Itself

Specialty pharmacy access involves both manufacturer distribution permission and the patient’s pharmacy network. Accreditation, network acceptance and permission to buy a limited-distribution drug are separate requirements.

The agency’s Part D guidance ties special handling requirements to the particular drug. It also speaks directly to reimbursement as an access barrier:

That gives an insider a concrete comparison: the drug’s actual handling requirements, the pharmacy’s capabilities, the terms offered and the rule used to route the prescription elsewhere. We want to know how the stated access promise worked at the counter.

Where the Affiliate Enters the Transaction

Steering to an affiliated pharmacy sends dispensing revenue to a business under the same ownership or control as the benefit administrator. The pharmacy benefit manager can set the network terms while its pharmacy earns money filling the prescription. We follow both payments: what the client pays for administration and what the owned pharmacy receives for dispensing.

The Centers for Medicare & Medicaid Services describes pharmacy benefit manager functions that include network contracting, pharmacy payment levels, rebate negotiations, formulary management and drug utilization review. A rebate aggregator may negotiate manufacturer payments, while a pharmacy services administrative organization may negotiate network contracts for pharmacies.

The business name on the building is only the beginning. We connect the entity that signed the network agreement to the entity that processed the claim, set reimbursement, received manufacturer money and supplied the sponsor’s report. In Part D, the sponsor retains responsibility for its CMS contract when it delegates work.

What the Client Was Promised

A promise to pass through rebates has a defined reach. Minnesota’s Caremark agreement effective in 2021 promises 100% of defined rebates received by the PBM or an affiliate. Its definition excludes described mail and specialty purchasing discounts and specified specialty-service revenue.

That distinction matters when the prescription goes to an owned pharmacy. The client’s rebate report and the affiliate’s dispensing or purchasing income can describe different parts of the same business. We examine what the client was told about those receipts, which categories the contract includes and how the final reconciliation treated them.

When Steering Changes a Government Payment

A steering decision reaches government money through the pharmacy payment and the reports that follow it. We connect where the prescription went, what the pharmacy benefit manager promised and what it told the payer about the cost.

The False Claims Act reaches knowingly false claims and false records that matter to government payment. Internal warnings, reporting instructions and the response to a known discrepancy can connect the decision to the payment.

Part D provides a concrete example. Its drug-cost reporting reaches qualifying rebates and other price concessions retained by an intermediary. What a sponsor is entitled to receive under its PBM contract and what must be reported to CMS are separate questions. A concession can affect federal reimbursement even when the PBM keeps it.

The pharmacy payment also changes over time. The Part D negotiated-price change took effect in 2024, bringing pharmacy concessions into the initial price. Later reporting still connects the estimated concession with final reimbursement. For a reimbursement allegation, the price at the counter, later adjustment and annual report belong together.

We examine the payer and the service year with you. Medicare Part D reporting, a Medicaid contract and a federal employee plan’s purchasing terms each supply their own obligations. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

The Records That Connect the Referral to the Money

The useful evidence follows the prescription from the routing decision through final payment. Different employees see different parts of it.

Network contracting staff may know the standard offer and the exception an affiliate received. The Centers for Medicare & Medicaid Services calls for a contracting log recording offers and negotiations with prospective pharmacies. That log puts an excluded pharmacy’s account beside the terms actually offered.

Pharmacy and claims staff can compare the member’s routing letter with the claim response. Pickup or delivery records connect payment to medicine the patient received. Reversals and final remittances show what happened to the money afterward.

Finance and reporting staff see manufacturer receipts and year-end adjustments. In Part D, the prescription drug event record is a summary extract from the claim transaction. Its corrections and the annual direct and indirect remuneration report connect the pharmacy payment to federal reconciliation.

An employee handling the network may never see the rebate file. An employee preparing the rebate file may never see the member letter. We bring those accounts together around the same drug, pharmacy, payer and period. That is how an access complaint becomes a specific account of who made the promise and where the money went.

What the Cases Show Beyond the Referral

Medco’s Promised Mail-Order Service

Medco’s mail-order case shows why the service behind the network promise matters. In its 2006 settlement announcement, the Justice Department alleged that Medco canceled valid prescriptions it could not fill on time to avoid contractual penalties, shorted pills and failed to perform required drug reviews. The government joined cases brought by whistleblowers over services for federal employees, retirees and their families.

The mail-order agreement’s allegations also included fabricated physician-contact records and manipulated prescription-receipt dates. Turnaround reports and invoices could tell a different story from the pharmacy’s work. The alleged shortcut was extraordinary: cancel the patient’s prescription to make the service failure disappear.

Caremark’s Pharmacy Payments Reduced Another Bill

An actuary brought Caremark’s whistleblower case, and the government declined to join. A 2025 court decision found that Caremark’s pricing agreements combined commercial and Part D purchases at Walgreens and Rite Aid. Higher Part D pharmacy payments reduced Caremark’s commercial reconciliation obligations. The court found those offsets were price concessions that the Part D reports had to reflect, even without a separate refund check.

The court found $95 million in government losses and entered a $289,873,500 judgment against Caremark Rx, CaremarkPCS Health and CVS Caremark Part D Services. It rejected liability for parent CVS Health. The responsibility followed the operating companies and the particular reporting arrangement.

For someone in reimbursement or finance, the telling documents were reconciliation workbooks, pricing material and sponsor-reporting attestations. We see the problem plainly: Caremark got a lower bill, and Medicare got an incomplete report.

Elixir’s Retained Rebates Became Service Fees

In the Elixir settlement agreement, the government alleged that retained manufacturer rebates were classified as service fees and excluded from annual Part D reports. Elixir Insurance Company was the sponsor. Elixir Rx Options and Elixir Rx Solutions were PBMs. The alleged classification affected the government’s reconciliation of plan payments.

The retained amounts came from a share of estimated rebates in the earlier years and a share of wholesale acquisition cost in the later year. An insider comparing the labels needs the manufacturer agreement, receipts and reporting treatment. For a network insider, the trail continues after the pharmacy fills the prescription: where did the manufacturer’s money go, and how was it reported? Changing its name can change what the government is told about the cost of health care.

Network Admission as the Price of Prescribing

A separate manufacturer-network allegation shows why ownership belongs beside the referral terms. A whistleblower alleged that pain management physicians held an interest in Patient Rx Solutions and refused to prescribe kaleo’s Evzio until that pharmacy entered kaleo’s network:

The alleged bargain made network admission valuable because the physicians could profit through their pharmacy ownership. Here the routing question starts with who wanted the pharmacy admitted and what prescribing business they offered in return.

Whose Savings Does the Network Deliver?

A network’s savings claim needs to identify whose cost fell: the patient’s, the sponsor’s or the dispensing business’s. The distinction changes what an insider should compare.

Comparing pharmacies within four selected integrated Part D sponsors, the Government Accountability Office’s 2026 analysis found lower payments and cost sharing at owned pharmacies for at least 94% of the 100 highest-utilization drugs in 2023. Owned pharmacies were predominantly mail order, while the comparison pharmacies were predominantly retail.

The HHS Office of Inspector General’s comparison of integrated and other Part D sponsors, also using selected drugs from that year, found nearly 40% higher out-of-pocket spending among sampled enrollees without financial assistance in integrated sponsors’ plans. The plans’ net costs were similar, even as those patients paid more.

We want a healthcare savings promise to say who saved. Which drugs and members did it cover, and did later rebates and adjustments change the result? The member’s cost sharing, the pharmacy’s reimbursement and the client’s final cost each deserve their own answer.

When You Know Why the Prescription Moved

If you know the network promise, the routing instruction or the affiliate payment that the client never saw, speak with our whistleblower experts about that transaction. We work beside you to connect the access decision to the contracts, reports and government money behind it. We bring in PBM fraud whistleblower lawyers who understand pharmacy reimbursement and benefit reporting, and stay with you through the case.